title: Diabetic nephropathy in 2014: improved cardiorenal prognosis in diabetic nephropathy.
abstract: In 2014, key studies in the field of diabetic nephropathy highlighted the importance of albuminuria as a predictor of cardiovascular risk and showed that the incidence of renal and cardiovascular complications is decreasing. Promising efficacy data were obtained with atrasentan, whereas a trial of bardoxolone methyl led to safety concerns.
authors.affiliation: Department of Medical Endocrinology, Rigshopsitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
authors.forename: Hans-Henrik
authors.initials: HH
authors.lastname: Parving
authors.affiliation: Steno Diabetes Center Niels Steensens Vej 2, 2820 Gentofte, Denmark.
authors.forename: Peter
authors.initials: P
authors.lastname: Rossing
mesh_terms: D000077868:Atrasentan; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000188:drug therapy; D065128:Endothelin Receptor Antagonists / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis; D011759:Pyrrolidines / Q000627:therapeutic use
chemical_list: D065128:Endothelin Receptor Antagonists; D011759:Pyrrolidines; D000077868:Atrasentan